Coverage
-
February 04, 2015
A Florida federal judge signed off Wednesday on a $1.25 million settlement that ends a class action brought by stockholders of Accentia Biopharmaceuticals Inc. and a subsidiary accusing the companies of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development.
2 other articles on this case.
View all »